Which has the lower trailing P/E, ALNY or IDXX?

IDXX has the lower trailing P/E: ALNY trades at 45.17 and IDXX at 38.17. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ALNY or IDXX?

Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus IDXX at 8.37%.

Is ALNY or IDXX more profitable?

IDXX runs the higher net margin — ALNY at 16.82% versus IDXX at 25.03%.

How have ALNY and IDXX total returns compared?

Over the past 10 years, ALNY delivered 14.48% and IDXX delivered 16.80% annualized total return. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs IDEXX Laboratories, Inc. (IDXX)

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and IDEXX Laboratories, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 3, 2026. Differences are shown without an overall score or investment verdict.

ALNY

Alnylam Pharmaceuticals, Inc.

$35.37B

$264.30HealthcareDelayed quote: Sep 3, 2026, 12:55 PM EDT

IDXX

IDEXX Laboratories, Inc.

$41.95B

$531.76HealthcareDelayed quote: Sep 3, 2026, 12:55 PM EDT

Total return — ALNY vs IDXX

growth of $100 · dividends reinvested · last 10y

ALNY +268.7% (+13.9%/yr)IDXX +376.7% (+16.9%/yr)IDXX compounded faster over this window

ALNY IDXX

ALNY vs IDXX: by the numbers

•IDXX is the larger company ($41.95B vs $35.37B market cap).
•IDXX trades at the lower trailing earnings multiple (38.17 vs 45.17 P/E), one valuation lens rather than an overall verdict.
•IDXX converts more revenue to profit (25.03% vs 16.82% net margin).
•ALNY grew revenue faster over the past five years (47.53% vs 8.37% CAGR).

Metrics side by side

Valuation

Metric	ALNY	IDXX
P/E ratio	45.17	38.17
Forward P/E	39.80	36.49
P/S ratio	7.69	9.55
P/B ratio	27.30	26.96
EV / EBITDA	34.65	27.52
FCF yield	1.47%	2.88%

Profitability

Metric	ALNY	IDXX
Gross margin	79.72%	62.45%
Operating margin	20.81%	32.03%
Net margin	16.82%	25.03%
ROE	59.67%	70.67%
ROIC	24.71%	41.33%

Growth (annualized)

Metric	ALNY	IDXX
Revenue CAGR (5Y)	47.53%	8.37%
EPS CAGR (5Y)	N/A	14.07%
FCF CAGR (5Y)	N/A	12.49%
Total return CAGR (5Y)	5.96%	-4.69%

Frequently asked

Which has the lower trailing P/E, ALNY or IDXX?: IDXX has the lower trailing P/E: ALNY trades at 45.17 and IDXX at 38.17. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ALNY or IDXX?: Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus IDXX at 8.37%.
Is ALNY or IDXX more profitable?: IDXX runs the higher net margin — ALNY at 16.82% versus IDXX at 25.03%.
How have ALNY and IDXX total returns compared?: Over the past 10 years, ALNY delivered 14.48% and IDXX delivered 16.80% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full IDXX analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio IDEXX Laboratories P/E ratio Alnylam Pharmaceuticals ROE IDEXX Laboratories ROE Alnylam Pharmaceuticals operating margin IDEXX Laboratories operating margin Alnylam Pharmaceuticals revenue growth IDEXX Laboratories revenue growth Alnylam Pharmaceuticals free cash flow IDEXX Laboratories free cash flow

Alnylam Pharmaceuticals & IDEXX Laboratories appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 3, 2026.